What Has Been the Growth of the Retinal Vein Occlusion Market So Far?
The retinal vein occlusion market has seen considerable growth due to a variety of factors.
• The market size for retinal vein occlusion has seen a fast-paced expansion in the previous years. It is predicted to surge from $15.43 billion in 2024 to $17.21 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.6%.
The substantial growth during the historic period is due to factors such as an aging population, progress in diagnostic imaging, pharmaceutical advancements, and a rise in diabetes prevalence.
What Are the Future Growth Projections for the Retinal Vein Occlusion Market?
The retinal vein occlusion market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market size of retinal vein occlusion is anticipated to undergo swift expansion. It is predicted to reach $25.66 billion by 2029 with a compound annual growth rate (CAGR) of 10.5%.
The rise during the forecasted period can be credited to innovative therapy methods, telemedicine and remote supervision, personal medicine, and regulatory approvals. Major trends within this period include non-invasive therapy possibilities, advancements in gene therapy, patient-oriented care, and digital health utilities.
What Are The Core Factors Supporting Growth In The Retinal Vein Occlusion Market?
The ocular drug delivery market is poised to witness considerable growth, owing to the heightened prevalence of eye disorders. Various conditions detrimental to the eyes, their surrounding structures, or vision, fall under the banner of eye disorders. The renal vein occlusion market also sees an upswing, propelled by the increasing cases of renal vein occlusion. The market expresses an urgent requirement for novel diagnostics and treatment methodologies to tackle this health issue. As per the World Health Organization's projections in March 2023, approximately 2.2 billion people across the world are expected to suffer near- or far-sighted impairment. Cataracts (94 million) and uncorrected refractive issues (88.4 million) are chief contributors to this visual loss or impairment. Other prevalent causes of vision loss are glaucoma (7.7 million instances), corneal opacities (4.2 million instances), diabetic retinopathy (3.9 million instances), and trachoma (2 million instances). The growing rate of eye disorders is, in turn, expected to catalyze the growth of the retinal vein occlusion market.
Retinal Vein Occlusion Market Driver: Surge in Glaucoma Diagnoses Sustains Expansion of Retinal Vein Occlusion Market
What Are The Major Segments Within The Global Retinal Vein Occlusion Market?
The retinal vein occlusion market covered in this report is segmented –
1) By Type: Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion
2) By Condition: Non-Ischemic, Ischemic
3) By Diagnosis: Optical Coherence Tomography, Fundoscopic Examination, Fluorescein Angiography
4) By Treatment: Antivascular Endothelial Growth Factor, Corticosteroid Drugs, Laser Retinal Photocoagulation
5) By End User: Hospitals And Clinics, Research And Academics Centers, Other End-Users
Subsegments:
1) By Branch Retinal Artery Occlusion: Non-ischemic Branch Retinal Artery Occlusion, Ischemic Branch Retinal Artery Occlusion
2) By Central Retinal Vein Occlusion: Non-ischemic Central Retinal Vein Occlusion, Ischemic Central Retinal Vein Occlusion
Pre-Book The Retinal Vein Occlusion Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Retinal Vein Occlusion Market?
The retinal vein occlusion market is witnessing the adoption of innovative strategies by companies to improve patient care as well as treatment results in order to consolidate their market position. The progress in the development of medicines has the potential to expand treatment alternatives for RVO, leading to more specialized and successful treatment. As an example, Iridex Corporation, an ophthalmic medical technology firm based in the United States, debuted its next-generation Iridex PASCAL in April 2023. This revolutionary platform offers a state-of-the-art technology bundle that merges rapid and precise pattern scanning capabilities, endpoint management technology, a pattern scanning laser trabeculoplasty, and micropulse technology into a small, ergonomically designed integrated laser platform to deliver personalized care to retinal disease patients.
Who Are the Key Players In The Retinal Vein Occlusion Market?
Major companies operating in the retinal vein occlusion market are:
• Pfizer Inc.
• Roche Holding AG
• Merck & Co. Inc.
• Bayer AG
• Novartis AG
• Bristol-Myers Squibb Company
• Amgen Inc.
• Allergan PLC
• Regeneron Pharmaceuticals Inc.
• Biogen Idec Inc.
• Vertex Pharmaceuticals Inc.
• Bausch Health Companies Inc.
• Carl Zeiss AG
• Santen Pharmaceutical Co. Ltd.
• Lumenis Ltd.
• Coherus Biosciences Inc.
• Genentech Inc.
• Topcon Corporation
• Nidek Co. Ltd.
• IRIDEX Corporation
• Alimera Sciences Inc.
• Ocular Therapeutix Inc.
• EyePoint Pharmaceuticals Inc.
• Kodiak Sciences Inc.
• Ellex Medical Lasers Ltd.
• Adverum Biotechnologies Inc.
• Avik Pharmaceutical Limited (Avik)
• Outlook Therapeutics Inc.
• Annexin Pharmaceuticals AB
• Ingenia Therapeutics Inc.
What Is The Most Dominant Region In The Retinal Vein Occlusion Market?
North America was the largest region in the retinal vein occlusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in retinal vein occlusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
